World Healthy Lifestyle Awareness Day: The Power of AI for Personalised Health

By Sumona Bose

February 15, 2024

Introduction

In today’s fast-paced world, where hectic schedules and demanding lifestyles have become the norm, maintaining a healthy lifestyle has never been more important. As we commemorate World Healthy Lifestyle Awareness Day (15th of February), it is crucial to recognise the role that artificial intelligence (AI) and Machine Learning (ML).  ML is a subset of AI which can be positioned to differentiate between correct and incorrect categorisations. The power of AI in personalised health can improve our attitudes towards health accordingly.

AI has made significant strides in recent years, enabling the development of sophisticated applications and tools that can assess trends in outcome-based research. AI advancements pave the way for healthcare interventions such as biological evaluations, diagnostics and predictions through devices. This has led to a more personalised collection of data and real-time feedback from customers.

Diseases 11 00097 g001 550
Figure 1: A schematic representation of the most commonly known AI methods.

Nutrition Assessments and AI

One area where AI can have a profound impact is in nutrition assessments. By collecting and evaluating data about dietary intake, AI systems can provide tailored diets that fit an individual’s behaviours. Factors such as age, gender, microbiota, genetics, metabolism, and lifestyle habits can all influence how individuals respond to food nutrients. The adoption of AI in the field of nutrition could pave the way for the development of personalised nutrition plans. This can eventually lead to better health outcomes at both the individual and national levels. AI technologies can enable precise customised dietary recommendations and promote health through predictive and preventive guidelines. This facilitates the management of diseases in a more effective manner.

AI Enabling Holistic Health Interventions

AI can assist physicians in selecting appropriate therapies, adjusting doses in a timely manner, and identifying patients who require more comprehensive or urgent examinations. By reducing the time spent in face-to-face visits and streamlining healthcare processes, AI can alleviate the workload of physicians and decrease waiting times in medical centres. This, in turn, can lead to a reduction in overall healthcare costs. The power of AI in personalised health delivers context specific health outcomes.

Conclusion

It is important to address certain challenges, related to patient privacy whilst acknowledging AI’s utility. Healthcare institutions and research collaborations produce methods in which AI is implemented responsibly and ethically. As we celebrate World Healthy Lifestyle Awareness Day, let us celebrate AI and personalised healthcare.

Reference url

Recent Posts

Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerative Colitis Treatment

By HEOR Staff Writer

October 9, 2025

The U.S. Food and Drug Administration has granted Simponi pediatric approval for Johnson & Johnson's Simponi (golimumab), which is intended for children with moderately to severely active ulcerative colitis who weigh at least 15 kg. This historic approval is backed by data from the PURSUIT pr...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications

By João L. Carapinha

October 6, 2025

The U.S. Food and Drug Administration (FDA) has recently approved lurbinectedin SCLC therapy in combination with atezolizumab, or with atezolizumab and hyaluronidase-qvfc, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This regulatory decision reflects ...